[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Erenumab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Erenumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Erenumab.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Erenumab.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of adverse effects can be increased when Erenumab is combined with Varicella zoster vaccine (live/attenuated).]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Erenumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Erenumab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Erenumab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Erenumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Erenumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Erenumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Erenumab.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Erenumab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Erenumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Erenumab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Alirocumab is combined with Erenumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Evolocumab is combined with Erenumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Idarucizumab is combined with Erenumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Erenumab.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Erenumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daratumumab is combined with Erenumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Necitumumab is combined with Erenumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Erenumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Erenumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Erenumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Erenumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Erenumab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Erenumab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Erenumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Erenumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Erenumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Avelumab is combined with Erenumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Erenumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Dupilumab is combined with Erenumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Erenumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Durvalumab is combined with Erenumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Erenumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Erenumab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Erenumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Erenumab.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Erenumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Benralizumab is combined with Erenumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Emicizumab is combined with Erenumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Ibalizumab is combined with Erenumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Burosumab is combined with Erenumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Erenumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Erenumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Erenumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Galcanezumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Emapalumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Erenumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Erenumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Romosozumab is combined with Erenumab.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Erenumab.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Erenumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Erenumab is combined with Trastuzumab deruxtecan.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Erenumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Eptinezumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Erenumab.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Inebilizumab is combined with Erenumab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Erenumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Erenumab.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Erenumab is combined with Margetuximab.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Erenumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Erenumab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Sotrovimab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Aducanumab is combined with Erenumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Erenumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Erenumab is combined with Tisotumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Tralokinumab is combined with Erenumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Sutimlimab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Tremelimumab is combined with Erenumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Ublituximab is combined with Erenumab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Erenumab.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Bimekizumab is combined with Erenumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Erenumab.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Erenumab.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Erenumab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Erenumab.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Erenumab.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Erenumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Erenumab.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Erenumab.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Erenumab.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Erenumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Erenumab.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Erenumab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Erenumab.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Erenumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Erenumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Erenumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Erenumab.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Erenumab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Erenumab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Erenumab.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Erenumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Erenumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Erenumab.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Erenumab.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The risk or severity of adverse effects can be increased when Erenumab is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).]
[J07AM01, tetanus toxoid vaccine, inactivated, The risk or severity of adverse effects can be increased when Erenumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Edrecolomab is combined with Erenumab.]
[J07AJ, pertussis vaccine, The risk or severity of adverse effects can be increased when Erenumab is combined with Pertussis vaccine.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Erenumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Erenumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Erenumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Erenumab.]
[J06BB05, rabies immune globulin, human, The risk or severity of adverse effects can be increased when Erenumab is combined with Rabies immune globulin, human.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Erenumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Erenumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Erenumab.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Erenumab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Erenumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Erenumab.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Erenumab.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of adverse effects can be increased when Erenumab is combined with Varicella zoster vaccine (live/attenuated).]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Erenumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Erenumab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Erenumab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Erenumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Erenumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Erenumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Erenumab.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Erenumab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Erenumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Erenumab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Alirocumab is combined with Erenumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Evolocumab is combined with Erenumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Idarucizumab is combined with Erenumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Erenumab.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Erenumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daratumumab is combined with Erenumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Necitumumab is combined with Erenumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Erenumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Erenumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Erenumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Erenumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Erenumab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Erenumab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Erenumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Erenumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Erenumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Avelumab is combined with Erenumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Erenumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Dupilumab is combined with Erenumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Erenumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Durvalumab is combined with Erenumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Erenumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Erenumab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Erenumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Erenumab.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Erenumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Benralizumab is combined with Erenumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Emicizumab is combined with Erenumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Ibalizumab is combined with Erenumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Burosumab is combined with Erenumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Erenumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Erenumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Erenumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Galcanezumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Emapalumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Erenumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Erenumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Romosozumab is combined with Erenumab.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Erenumab.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Erenumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Erenumab is combined with Trastuzumab deruxtecan.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Erenumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Eptinezumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Erenumab.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Inebilizumab is combined with Erenumab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Erenumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Erenumab.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Erenumab is combined with Margetuximab.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Erenumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Erenumab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Sotrovimab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Aducanumab is combined with Erenumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Erenumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Erenumab is combined with Tisotumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Erenumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Tralokinumab is combined with Erenumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Sutimlimab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Erenumab is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Tremelimumab is combined with Erenumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Ublituximab is combined with Erenumab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Erenumab.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Bimekizumab is combined with Erenumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Erenumab.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Erenumab.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Erenumab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Erenumab.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Erenumab.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Erenumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Erenumab.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Erenumab.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Erenumab.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Erenumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Erenumab.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Erenumab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Erenumab.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Erenumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Erenumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Erenumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Erenumab.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Erenumab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Erenumab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Erenumab.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Erenumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Erenumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Erenumab.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Erenumab.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The risk or severity of adverse effects can be increased when Erenumab is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).]
[J07AM01, tetanus toxoid vaccine, inactivated, The risk or severity of adverse effects can be increased when Erenumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Edrecolomab is combined with Erenumab.]
[J07AJ, pertussis vaccine, The risk or severity of adverse effects can be increased when Erenumab is combined with Pertussis vaccine.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Erenumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Erenumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Erenumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Erenumab.]
[J06BB05, rabies immune globulin, human, The risk or severity of adverse effects can be increased when Erenumab is combined with Rabies immune globulin, human.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Erenumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Erenumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Erenumab.]
